Merck & Co., Inc. Financial Highlights Package Third Quarter 2021 Table of Contents Table 1: GAAP P&L....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2 Table 2a: GAAP to Non-GAAP Reconciliation 3Q21 and Sept YTD 21.......3 Table 2b: GAAP to Non-GAAP Reconciliation 3Q20 and Sept YTD 20......4 Table 3: Sales - Current Year and Prior Year by Quarter...........................5 Table 3a: Sales – U.S. / Ex- U.S. 3Q21........................................................6 Table 3b: Sales – U.S. / Ex- U.S. Sept YTD 21............................................7 Table 3c: Sales – Pharmaceutical Geographic Split....................................8 Table 4: Other (Income) Expense .............................................................9 -- 1 of 10 -- Sales 13,154 $ 10,929 $ 20% 35,183 $ 30,570 $ 15% Costs, Expenses and Other Cost of sales 3,450 3,013 15% 9,752 8,589 14% Selling, general and administrative 2,336 2,060 13% 6,804 6,336 7% Research and development 2,445 3,349 -27% 9,177 7,609 21% Restructuring costs (1) 107 113 -5% 487 265 84% Other (income) expense, net (450) (312) 44% (1,007) (637) 58% Income from Continuing Operations Before Taxes 5,266 2,706 95% 9,970 8,408 19% Income Tax Provision 695 380 1,436 1,271 Net Income from Continuing Operations 4,571 2,326 97% 8,534 7,137 20% Less: Net Income Attributable to Noncontrolling Interests 4 2 9 1 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,567 $ 2,324 $ 97% 8,525 $ 7,136 $ 19% Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests - $ 617 $ * 766 $ 2,025 $ -62% Net Income Attributable to Merck & Co., Inc. 4,567 $ 2,941 $ 55% 9,291 $ 9,161 $ 1% Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.81 $ 0.92 $ 97% 3.37 $ 2.82 $ 20% Income from Discontinued Operations - $ 0.24 $ * 0.30 $ 0.80 $ -63% Net Income 1.81 $ 1.16 $ 56% 3.67 $ 3.62 $ 1% Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.80 $ 0.92 $ 96% 3.36 $ 2.81 $ 20% Income from Discontinued Operations - $ 0.24 $ * 0.30 $ 0.80 $ -63% Net Income 1.80 $ 1.16 $ 55% 3.66 $ 3.61 $ 1% Average Shares Outstanding 2,530 2,529 2,531 2,530 Average Shares Outstanding Assuming Dilution 2,536 2,538 2,539 2,541 Tax Rate from Continuing Operations (2) 13.2% 14.0% 14.4% 15.1% * 100% or greater (2) The effective income tax rate for the first nine months of 2021 reflects the unfavorable impact of a charge for the acquisition of Pandion Therapeutics, Inc. for which no tax benefit was recognized and a net tax benefit of $207 million related to the settlement of certain federal income tax matters. MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 GAAP % Change GAAP % Change 3Q21 On June 2, 2021, Merck completed the spinoff of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to company shareholders. The historical results of the women’s health, biosimilars and established brands businesses that were contributed to Organon in the spin-off are excluded from sales and expenses below and reflected as discontinued operations in the company’s Consolidated Statements of Income provided below. 3Q20 Sep YTD 2021 Sep YTD 2020 (1) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs. 1 -- 2 of 10 -- Sales 10,627 $ 11,402 $ 13,154 $ 35,183 $ 10,288 $ 9,353 $ 10,929 $ 30,570 $ 10,948 $ 41,518 $ 20% 15% Costs, Expenses and Other Cost of sales 3,199 3,104 3,450 9,752 2,829 2,747 3,013 8,589 5,029 13,618 15% 14% Selling, general and administrative 2,187 2,281 2,336 6,804 2,191 2,085 2,060 6,336 2,619 8,955 13% 7% Research and development 2,412 4,321 2,445 9,177 2,175 2,085 3,349 7,609 5,788 13,397 -27% 21% Restructuring costs 297 82 107 487 70 82 113 265 310 575 -5% 84% Other (income) expense, net (455) (103) (450) (1,007) 62 (387) (312) (637) (253) (890) 44% 58% Income (Loss) from Continuing Operations Before Taxes 2,987 1,717 5,266 9,970 2,961 2,741 2,706 8,408 (2,545) 5,863 95% 19% Income Tax Provision 238 503 695 1,436 495 396 380 1,271 69 1,340 Net Income (Loss) from Continuing Operations 2,749 1,214 4,571 8,534 2,466 2,345 2,326 7,137 (2,614) 4,523 97% 20% Less: Net Income (Loss) Attributable to Noncontrolling Interests 4 1 4 9 (5) 4 2 1 3 4 Net Income (Loss) from Continuing Operations Attributable to Merck & Co., Inc. 2,745 1,213 4,567 8,525 2,471 2,341 2,324 7,136 (2,617) 4,519 97% 19% Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 434 332 - 766 748 661 617 2,025 523 2,548 * -62% Net Income (Loss) Attributable to Merck & Co., Inc. 3,179 $ 1,545 $ 4,567 $ 9,291 $ 3,219 $ 3,002 $ 2,941 $ 9,161 $ (2,094) $ 7,067 $ 55% 1% Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income (Loss) from Continuing Operations 1.08 $ 0.48 $ 1.81 $ 3.37 $ 0.98 $ 0.93 $ 0.92 $ 2.82 $ (1.03) $ 1.79 $ 97% 20% Income from Discontinued Operations 0.17 0.13 - 0.30 0.30 0.26 0.24 0.80 0.21 1.01 * -63% Net Income (Loss) 1.26 $ 0.61 $ 1.81 $ 3.67 $ 1.27 $ 1.19 $ 1.16 $ 3.62 $ (0.83) $ 2.79 $ 56% 1% Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income (Loss) from Continuing Operations 1.08 $ 0.48 $ 1.80 $ 3.36 $ 0.97 $ 0.92 $ 0.92 $ 2.81 $ (1.03) $ 1.78 $ 96% 20% Income from Discontinued Operations 0.17 0.13 - 0.30 0.29 0.26 0.24 0.80 0.21 1.00 * -63% Net Income (Loss) 1.25 $ 0.61 $ 1.80 $ 3.66 $ 1.26 $ 1.18 $ 1.16 $ 3.61 $ (0.83) $ 2.78 $ 55% 1% Average Shares Outstanding 2,531 2,533 2,530 2,531 2,533 2,527 2,529 2,530 2,530 2,530 Average Shares Outstanding Assuming Dilution (1) 2,541 2,540 2,536 2,539 2,547 2,536 2,538 2,541 2,530 2,541 Tax Rate from Continuing Operations 8.0% 29.3% 13.2% 14.4% 16.7% 14.4% 14.0% 15.1% -2.7% 22.9% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. % Change 3Q Sep YTD (1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. Income from discontinued operations was also computed using average common shares outstanding. 2021 2Q 3Q Sep YTD 1Q 1Q 2Q 3Q 4Q Full Year 2020 Sep YTD Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) 2 -- 3 of 10 -- Third Quarter Cost of sales 3,450 $ 346 48 394 3,056 $ Selling, general and administrative 2,336 61 5 66 2,270 Research and development 2,445 48 8 (87) (4) (31) 2,476 Restructuring costs 107 107 107 - Other (income) expense, net (450) (10) (684) (694) 244 Income From Continuing Operations Before Taxes 5,266 (445) (168) 684 87 158 5,108 Income Tax Provision (Benefit) 695 (96) (5) (26) (5) 151 (5) 1 (5) 30 665 Net Income from Continuing Operations 4,571 (349) (142) 533 86 128 4,443 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,567 (349) (142) 533 86 128 4,439 Earnings per Common Share Assuming Dilution from Continuing Operations 1.80 $ (0.14) (0.06) 0.21 0.04 0.05 1.75 $ Tax Rate 13.2% 13.0% Sep YTD Cost of sales 9,752 $ 1,188 113 225 (3) 1,526 8,226 $ Selling, general and administrative 6,804 96 9 105 6,699 Research and development 9,177 82 21 1,678 (4) 1,781 7,396 Restructuring costs 487 487 487 - Other (income) expense, net (1,007) 79 (1,503) (1,424) 417 Income From Continuing Operations Before Taxes 9,970 (1,445) (630) 1,503 (1,903) (2,475) 12,445 Income Tax Provision (Benefit) 1,436 (283) (5) (82) (5) 331 (5) (259) (5) (293) 1,729 Net Income from Continuing Operations 8,534 (1,162) (548) 1,172 (1,644) (2,182) 10,716 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 8,525 (1,162) (548) 1,172 (1,644) (2,182) 10,707 Earnings per Common Share Assuming Dilution from Continuing Operations 3.36 $ (0.46) (0.22) 0.46 (0.65) (0.86) 4.22 $ Tax Rate 14.4% 13.9% Only the line items that are affected by non-GAAP adjustments are shown. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect acquisition and divestiture-related costs. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the third quarter and nine months period primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture. Additionally, the first nine months also includes a loss on a forward exchange contract entered into in conjunction with the Organon spinoff. Amount included in other (income) expense, net, for the nine month period is partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents charges for the discontinuation of COVID-19 development programs. (5) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the nine month period also includes a $207 million net tax benefit related to the settlement of certain federal income tax matters. (4) Amounts included in the third quarter and first nine months reflect a $90 million adjustment to deferred tax assets identified in conjunction with the VelosBio Inc. acquisition. Additionally, the first nine months includes a $1.7 billion charge for the acquisition of Pandion Therapeutics, Inc. Adjustment Subtotal Non-GAAP MERCK & CO., INC. THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Table 2a 3 -- 4 of 10 -- Third Quarter Cost of sales 3,013 $ 403 38 441 2,572 $ Selling, general and administrative 2,060 25 15 40 2,020 Research and development 3,349 19 19 1,082 (3) 1,120 2,229 Restructuring costs 113 113 113 - Other (income) expense, net (312) (346) (1) (347) 35 Income From Continuing Operations Before Taxes 2,706 (447) (185) 346 (1,081) (1,367) 4,073 Income Tax Provision (Benefit) 380 (9) (4) (25) (4) 76 (4) (247) (4) (205) 585 Net Income from Continuing Operations 2,326 (438) (160) 270 (834) (1,162) 3,488 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 2,324 (438) (160) 270 (834) (1,162) 3,486 Earnings per Common Share Assuming Dilution from Continuing Operations 0.92 $ (0.17) (0.06) 0.11 (0.33) (0.45) 1.37 $ Tax Rate 14.0% 14.4% Sep YTD Cost of sales 8,589 $ 1,370 131 1,501 7,088 $ Selling, general and administrative 6,336 182 37 219 6,117 Research and development 7,609 (4) 67 1,082 (3) 1,145 6,464 Restructuring costs 265 265 265 - Other (income) expense, net (637) 52 (944) (17) (909) 272 Income From Continuing Operations Before Taxes 8,408 (1,600) (500) 944 (1,065) (2,221) 10,629 Income Tax Provision (Benefit) 1,271 (251) (4) (59) (4) 208 (4) (242) (4) (344) 1,615 Net Income from Continuing Operations 7,137 (1,349) (441) 736 (823) (1,877) 9,014 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 7,136 (1,349) (441) 736 (823) (1,877) 9,013 Earnings per Common Share Assuming Dilution from Continuing Operations 2.81 $ (0.54) (0.17) 0.29 (0.32) (0.74) 3.55 $ Tax Rate 15.1% 15.2% Only the line items that are affected by non-GAAP adjustments are shown. The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below. MERCK & CO., INC. THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2020 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative (SG&A) expenses reflect acquisition and divestiture-related costs, including $95 million of transaction costs in the nine month period related to the acquisition of Arqule, Inc. Amounts included in research and development expenses primarily reflect a reduction in expenses related to a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net, primarily reflect costs related to increases in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (4) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Acquisition and divestiture-related costs also includes a tax cost of $67 million, representing an adjustment to the tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Adjustment Subtotal (3) Represents expenses for upfront payments related to license and collaboration agreements. 4 -- 5 of 10 -- 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $10,627 $11,402 $13,154 $35,183 $10,288 $9,353 $10,929 $30,570 $10,948 $41,518 20 19 15 13 PHARMACEUTICAL 9,238 9,980 11,496 30,714 8,905 8,178 9,714 26,797 9,813 36,610 18 17 15 12 Oncology Keytruda 3,899 4,176 4,534 12,609 3,284 3,388 3,715 10,387 3,993 14,380 22 21 21 19 Alliance Revenue – Lynparza (2) 228 248 246 721 145 178 196 519 206 725 25 25 39 35 Alliance Revenue – Lenvima (2) 130 181 188 498 128 151 142 421 158 580 32 30 18 15 Vaccines (3) Gardasil / Gardasil 9 917 1,234 1,993 4,144 1,097 656 1,187 2,941 998 3,938 68 63 41 35 ProQuad / M-M-R II / Varivax 449 516 661 1,626 435 378 576 1,390 488 1,878 15 14 17 16 Pneumovax 23 171 152 277 600 256 117 375 748 339 1,087 -26 -26 -20 -21 RotaTeq 158 208 227 593 222 168 210 601 196 797 8 7 -1 -3 Vaqta 34 56 48 138 60 28 51 139 31 170 -6 -6 -1 -2 Hospital Acute Care Bridion 340 387 369 1,096 299 224 320 843 355 1,198 16 15 30 27 Prevymis 82 93 96 270 60 63 77 200 80 281 23 22 35 31 Noxafil 67 66 64 197 94 73 79 247 82 329 -19 -20 -20 -23 Primaxin 65 60 70 194 51 64 74 189 62 251 -6 -12 3 -4 Cancidas 57 54 56 168 55 43 50 148 65 213 13 9 13 8 Invanz 57 48 53 157 64 43 51 159 53 211 5 0 -1 -4 Zerbaxa (8) (1) (2) (11) 37 32 43 112 19 130 -105 -105 -110 -110 Immunology Simponi 214 202 203 619 215 191 209 615 223 838 -3 -5 1 -5 Remicade 85 75 73 233 88 73 82 242 88 330 -11 -11 -4 -8 Neuroscience Belsomra 79 78 81 238 79 84 81 244 83 327 0 3 -2 -2 Virology Isentress / Isentress HD 209 192 189 590 245 196 205 646 211 857 -8 -7 -9 -9 Cardiovascular Alliance Revenue - Adempas/Verquvo (4) 74 74 100 248 53 79 83 216 65 281 20 20 15 15 Adempas (5) 55 74 59 188 56 57 55 167 53 220 7 8 13 7 Diabetes (6) Januvia 809 784 852 2,445 774 854 821 2,449 857 3,306 4 3 0 -3 Janumet 486 477 487 1,449 503 490 506 1,499 472 1,971 -4 -6 -3 -7 Other Pharmaceutical (7) 581 546 572 1,704 605 548 526 1,675 636 2,312 9 8 2 1 ANIMAL HEALTH 1,418 1,472 1,417 4,307 1,214 1,101 1,220 3,535 1,168 4,703 16 14 22 19 Livestock 819 821 864 2,503 739 648 758 2,145 794 2,939 14 12 17 14 Companion Animals 599 651 553 1,804 475 453 462 1,390 374 1,764 20 18 30 26 Other Revenues (8) (29) (50) 241 162 169 74 (5) 238 (33) 205 * * -32 88 * 200% or greater (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. (6) Total Diabetes sales were $1,363 million, $1,330 million, and $1,417 million in the first, second, and third quarter of 2021, respectively, and $1,353 million, $1,418 million, $1,405 million and $1,412 million in the first, second, third and fourth quarters of 2020, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the third quarter and September year-to-date period of 2021 include $135 million related to the receipt of a milestone payment for an out-licensed product. Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Total Vaccines sales were $1,809 million, $2,293 million, and $3,315 million in the first, second, and third quarter of 2021, respectively, and $2,155 million, $1,418 million, $2,521 million and $2,163 million in the first, second, third and fourth quarters of 2020, respectively. MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2021 2020 3Q September YTD 5 -- 6 of 10 -- 3Q 2021 3Q 2020 % Change 3Q 2021 3Q 2020 % Change 3Q 2021 3Q 2020 % Change TOTAL SALES (1) $13,154 $10,929 20 $6,276 $5,250 20 $6,878 $5,679 21 PHARMACEUTICAL 11,496 9,714 18 5,670 4,842 17 5,826 4,872 20 Oncology Keytruda 4,534 3,715 22 2,580 2,157 20 1,954 1,559 25 Alliance Revenue - Lynparza (2) 246 196 25 129 107 21 117 89 31 Alliance Revenue - Lenvima (2) 188 142 32 114 82 40 74 60 23 Vaccines (3) Gardasil / Gardasil 9 1,993 1,187 68 839 579 45 1,154 608 90 ProQuad / M-M-R II / Varivax 661 576 15 537 437 23 125 139 -10 Pneumovax 23 277 375 -26 181 276 -34 97 99 -3 RotaTeq 227 210 8 135 114 19 92 96 -4 Vaqta 48 51 -6 32 32 2 16 19 -19 Hospital Acute Care Bridion 369 320 16 181 162 11 188 157 20 Prevymis 96 77 23 39 32 22 57 46 24 Noxafil 64 79 -19 19 13 44 45 66 -31 Primaxin 70 74 -6 1 -64 69 73 -5 Cancidas 56 50 13 1 1 -19 56 49 14 Invanz 53 51 5 (2) 1 * 55 50 12 Zerbaxa (2) 43 -105 (1) 20 -106 (1) 23 -104 Immunology Simponi 203 209 -3 203 209 -3 Remicade 73 82 -11 73 82 -11 Neuroscience Belsomra 81 81 23 18 32 58 63 -8 Virology Isentress / Isentress HD 189 205 -8 77 92 -16 112 113 -1 Cardiovascular Alliance Revenue - Adempas/Verquvo (4) 100 83 20 73 78 -7 27 5 * Adempas (5) 59 55 7 0 - 59 55 7 Diabetes (6) Januvia 852 821 4 365 342 7 487 479 2 Janumet 487 506 -4 86 105 -18 401 400 Other Pharmaceutical (7) 572 526 9 262 193 36 308 333 -8 ANIMAL HEALTH 1,417 1,220 16 467 399 17 951 821 16 Livestock 864 758 14 190 165 15 675 593 14 Companion Animals 553 462 20 277 234 18 276 228 21 Other Revenues (8) 241 (5) * 139 9 * 101 (14) * * 200% or greater Sum of U.S. plus international may not equal global due to rounding. (8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the third quarter of 2021 include $135 million related to the receipt of a milestone payment for an out-licensed product. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Total Vaccines sales were $3,315 million in the third quarter of 2021 and $2,521 million in the third quarter of 2020. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. (6) Total Diabetes sales were $1,417 million in the third quarter of 2021 and $1,405 million in the third quarter of 2020. (7) Includes Pharmaceutical products not individually shown above. (1) Only select products are shown. MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS THIRD QUARTER 2021 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 6 -- 7 of 10 -- September YTD 2021 September YTD 2020 % Change September YTD 2021 September YTD 2020 % Change September YTD 2021 September YTD 2020 % Change TOTAL SALES (1) $35,183 $30,570 15 $16,166 $14,301 13 $19,017 $16,269 17 PHARMACEUTICAL 30,714 26,797 15 14,611 13,108 11 16,103 13,690 18 Oncology Keytruda 12,609 10,387 21 7,108 6,106 16 5,501 4,281 29 Alliance Revenue - Lynparza (2) 721 519 39 371 297 25 350 223 57 Alliance Revenue - Lenvima (2) 498 421 18 287 270 6 211 152 39 Vaccines (3) Gardasil / Gardasil 9 4,144 2,941 41 1,605 1,209 33 2,539 1,732 47 ProQuad / M-M-R II / Varivax 1,626 1,390 17 1,255 1,033 21 371 356 4 Pneumovax 23 600 748 -20 354 478 -26 247 270 -9 RotaTeq 593 601 -1 364 355 3 229 246 -7 Vaqta 138 139 -1 80 79 1 58 60 -4 Hospital Acute Care Bridion 1,096 843 30 545 412 32 551 431 28 Prevymis 270 200 35 111 87 28 159 113 40 Noxafil 197 247 -20 48 27 79 149 220 -32 Primaxin 194 189 3 2 -79 194 187 4 Cancidas 168 148 13 4 2 129 164 147 12 Invanz 157 159 -1 (2) 7 -128 159 152 5 Zerbaxa (11) 112 -110 (5) 57 -109 (6) 54 -111 Immunology Simponi 619 615 1 619 615 1 Remicade 233 242 -4 233 242 -4 Neuroscience Belsomra 238 244 -2 56 67 -17 183 177 3 Virology Isentress / Isentress HD 590 646 -9 222 243 -9 368 403 -9 Cardiovascular Alliance Revenue - Adempas/Verquvo (4) 248 216 15 222 200 11 26 16 67 Adempas (5) 188 167 13 0 - 188 167 13 Diabetes (6) Januvia 2,445 2,449 997 1,110 -10 1,448 1,339 8 Janumet 1,449 1,499 -3 244 361 -32 1,205 1,138 6 Other Pharmaceutical (7) 1,704 1,675 2 745 706 6 957 969 -1 ANIMAL HEALTH 4,307 3,535 22 1,363 1,124 21 2,944 2,411 22 Livestock 2,503 2,145 17 508 448 13 1,996 1,697 18 Companion Animals 1,804 1,390 30 855 676 26 948 714 33 Other Revenues (8) 162 238 -32 192 69 181 (30) 168 -118 Sum of U.S. plus international may not equal global due to rounding. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. (6) Total Diabetes sales were $4,110 million and $4,177 million on a global basis for September YTD 2021 and 2020, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the September year-to-date period of 2021 include $135 million related to the receipt of a milestone payment for an out-licensed product. (3) Total Vaccines sales were $7,417 million and $6,094 million on a global basis for September YTD 2021 and 2020, respectively. MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS SEPTEMBER YEAR-TO-DATE 2021 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. 7 -- 8 of 10 -- TOTAL PHARMACEUTICAL $9,238 $9,980 $11,496 $30,714 $8,905 $8,178 $9,714 $26,797 $9,813 $36,610 18 15 United States 4,294 4,647 5,670 14,611 4,308 3,958 4,842 13,108 4,903 18,010 17 11 % Pharmaceutical Sales 46.5% 46.6% 49.3% 47.6% 48.4% 48.4% 49.8% 48.9% 50.0% 49.2% Europe (1) 2,276 2,404 2,445 7,124 2,116 1,855 2,171 6,141 2,314 8,455 13 16 % Pharmaceutical Sales 24.6% 24.1% 21.3% 23.2% 23.8% 22.7% 22.3% 22.9% 23.6% 23.1% China 688 944 1,278 2,910 628 600 764 1,992 670 2,661 67 46 % Pharmaceutical Sales 7.4% 9.5% 11.1% 9.5% 7.1% 7.3% 7.9% 7.4% 6.8% 7.3% Japan 607 637 614 1,858 561 601 648 1,810 704 2,514 -5 3 % Pharmaceutical Sales 6.6% 6.4% 5.3% 6.0% 6.3% 7.3% 6.7% 6.8% 7.2% 6.9% Asia Pacific (other than China and Japan) 437 442 450 1,329 411 377 411 1,200 414 1,614 9 11 % Pharmaceutical Sales 4.7% 4.4% 3.9% 4.3% 4.6% 4.6% 4.2% 4.5% 4.2% 4.4% Latin America 353 379 434 1,166 314 312 372 998 371 1,369 17 17 % Pharmaceutical Sales 3.8% 3.8% 3.8% 3.8% 3.5% 3.8% 3.8% 3.7% 3.8% 3.7% Eastern Europe/Middle East/Africa 357 318 362 1,037 353 309 289 948 251 1,199 25 9 % Pharmaceutical Sales 3.9% 3.2% 3.1% 3.4% 4.0% 3.8% 3.0% 3.5% 2.6% 3.3% Canada 160 157 164 482 159 121 169 449 149 599 -3 7 % Pharmaceutical Sales 1.7% 1.6% 1.4% 1.6% 1.8% 1.5% 1.7% 1.7% 1.5% 1.6% Other 66 52 79 197 55 45 48 151 37 189 65 30 % Pharmaceutical Sales 0.8% 0.4% 0.8% 0.6% 0.5% 0.6% 0.6% 0.6% 0.3% 0.5% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 3Q Sep YTD 4Q Full Year 3Q Sep YTD 1Q 2Q 3Q Sep YTD 1Q 2Q 2021 2020 % Change MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 3Q21 3Q20 Sep YTD 2021 Sep YTD 2020 Interest income (7) $ (9) $ (27) $ (48) $ Interest expense 196 203 597 624 Exchange losses 46 10 202 89 Income from investments in equity securities, net (1) (683) (360) (1,535) (964) Net periodic defined benefit plan cost (credit) other than service cost 40 (88) (159) (259) Other, net (42) (68) (85) (79) Total (450) $ (312) $ (1,007) $ (637) $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --